Earnings Releases·Nov 2, 2026, 4:07 PM ET

BioMarin Pharmaceutical Inc. — Third Quarter 2026 Earnings Summary

BMRN

**Financial Performance:** Q3 2026 total revenue reached $1,025 million (32% YoY growth), with Non-GAAP income of $45 million and Non-GAAP diluted EPS of $0.23; however, GAAP net loss widened to $123 million due to integration costs, high interest expense, and significant acquired IPR&D charges.
**Strategic M&A and Capital Structure:** The company completed the acquisition of Amicus Therapeutics on April 27, 2026, resulting in a $4.68 billion net cash outflow for investing activities and a total debt increase to $4.17 billion, while expecting $280 million in GAAP cost synergies to be fully realized by 2028.
**Guidance Reduction:** Full-year 2026 Non-GAAP diluted EPS guidance was lowered to $2.80–$3.10 (from $4.90–$5.10) and total revenue guidance adjusted to $3,800–$3,900 million, reflecting order timing uncertainty from a single international customer and $403 million in pre-tax charges from the Alesta acquisition and BMN 450 license.
**Product and Pipeline Highlights:** Metabolic Conditions revenue grew 44% YoY driven by GALAFOLD and POMBILITI + OPFOLDA, while VOXZOGO revenue rose 12% YoY; regulatory milestones include a PDUFA date of February 28, 2027, for achondroplasia approval and May 30, 2027, for hypochondroplasia expansion.
**Settlement and Outlook:** A global settlement with Ascendis Pharma A/S regarding Yuviwel claims was announced on August 30, 2026, securing a 20% U.S. royalty on net sales until May 2030, while management maintains a positive outlook for 2027 growth driven by the diversified portfolio.

Company: BIOMARIN PHARMACEUTICAL INC
Sector: Healthcare
Industry: Biotechnology